These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 6622297)

  • 41. Effect of chronic desipramine treatment on dihydroalprenolol, imipramine, and desipramine binding sites: a quantitative autoradiographic study in the rat brain.
    Biegon A
    J Neurochem; 1986 Jul; 47(1):77-80. PubMed ID: 3011994
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Thyroid accumulation and adverse effects of imipramine and desipramine in rats after long-term administration.
    Rousseau A; Marquet P; Lagorce JF; Sauvage MF; Buxeraud J; Lachâtre G; Raby C
    Pharmacology; 1998 Nov; 57(5):242-8. PubMed ID: 9742289
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Synergistic effect of imipramine and amantadine in the forced swimming test in rats. Behavioral and pharmacokinetic studies.
    Rogóz Z; Skuza G; Kuśmider M; Wójcikowski J; Kot M; Daniel WA
    Pol J Pharmacol; 2004; 56(2):179-85. PubMed ID: 15156068
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Differential effects of cimetidine and ranitidine on imipramine demethylation and desmethylimipramine hydroxylation by human liver microsomes.
    Spina E; Koike Y
    Eur J Clin Pharmacol; 1986; 30(2):239-42. PubMed ID: 3709653
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Different pharmacokinetic and pharmacological effects following acute and chronic treatment with imipramine.
    Maj J; Melzacka M; Mogilnicka E; Daniel W
    J Neural Transm; 1982; 54(3-4):219-28. PubMed ID: 7130974
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Studies on the effect of cystamine on imipramine metabolism in radiation sickness.
    Chodera A; Cenajek D; Wójciak Z; Szczawiínska K; Kozaryn I
    Acta Physiol Pol; 1980; 31(1):41-6. PubMed ID: 7376897
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The relationship of plasma imipramine and N-desmethylimipramine to response in panic disorder.
    Mavissakalian MR; Perel JM
    Psychopharmacol Bull; 1996; 32(1):143-7. PubMed ID: 8927664
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Model for the kinetics of imipramine and its metabolites in adolescents.
    Dell RB; Hein K; Ramakrishnan R; Puig-Antich J; Cooper T
    Ther Drug Monit; 1990 Sep; 12(5):450-9. PubMed ID: 2293407
    [TBL] [Abstract][Full Text] [Related]  

  • 49. An approach to evaluate metabolite-related phototoxicity with combined use of photochemical properties and skin deposition.
    Seto Y; Tonami R; Iyama Y; Sato H; Onoue S
    Toxicol Lett; 2021 Oct; 350():91-97. PubMed ID: 34265374
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The route of administration of imipramine as a factor affecting formation of its metabolite desipramine.
    Daniel W; Adamus A; Melzacka M; Szymura J
    J Pharm Pharmacol; 1982 Oct; 34(10):678-80. PubMed ID: 6128396
    [No Abstract]   [Full Text] [Related]  

  • 51. On the mechanism of imipramine's influence in lowering p-hydroxyphenylglycol concentrations in the brain. The role of tyrosine.
    Edwards DJ; Sorisio DA; Sedlock ML
    Biochem Pharmacol; 1988 May; 37(10):2059-67. PubMed ID: 2837223
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effect of chronic desmethylimipramine or electroconvulsive shock on selected brain and platelet neurotransmitter recognition sites.
    Abel MS; Clody DE; Wennogle LP; Meyerson LR
    Biochem Pharmacol; 1985 Mar; 34(5):679-83. PubMed ID: 2983735
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Monitoring of serum levels of imipramine and desipramine and individualization of dose in enuretic children.
    de Gatta MF; García MJ; Acosta A; Rey F; Gutierrez JR; Dominguez-Gil A
    Ther Drug Monit; 1984; 6(4):438-43. PubMed ID: 6515703
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effects of joint administration of imipramine and amantadine in patients with drug-resistant unipolar depression.
    Rogóz Z; Dziedzicka-Wasylewska M; Daniel WA; Wójcikowski J; Dudek D; Wróbel A; Zieba A
    Pol J Pharmacol; 2004; 56(6):735-42. PubMed ID: 15662086
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effect of combined treatment with imipramine and amantadine on the central dopamine D2 and D3 receptors in rats.
    Rogóz Z; Dlaboga D; Dziedzicka-Wasylewska M
    J Physiol Pharmacol; 2003 Jun; 54(2):257-70. PubMed ID: 12832726
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Population pharmacokinetics of imipramine in children.
    Tamayo M; Fernández de Gatta MM; García MJ; Domínguez-Gil A
    Eur J Clin Pharmacol; 1992; 43(1):89-92. PubMed ID: 1505617
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Appropriate dosing regimens for treating juvenile rats with desipramine for neuropharmacological and behavioral studies.
    Kozisek ME; Deupree JD; Burke WJ; Bylund DB
    J Neurosci Methods; 2007 Jun; 163(1):83-91. PubMed ID: 17400296
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Imipramine-cimetidine interaction: impairment of clearance and enhanced absolute bioavailability.
    Abernethy DR; Greenblatt DJ; Shader RI
    J Pharmacol Exp Ther; 1984 Jun; 229(3):702-5. PubMed ID: 6726654
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Metabolism of imipramine in vitro by isozyme CYP2D6 expressed in a human cell line, and observations on metabolite stability.
    Coutts RT; Su P; Baker GB; Daneshtalab M
    J Chromatogr; 1993 Jun; 615(2):265-72. PubMed ID: 8335704
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The effect of imipramine on lipid peroxidation in the rat cerebral cortex.
    Melzacka M; Sas-Korczyńska A; Syrek M
    Pol J Pharmacol; 1995; 47(1):25-30. PubMed ID: 7550545
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.